2026-08-19
Dear Valued Partners and Colleagues,
We appreciate your continued trust in and support of Suzhou Tianji Biopharma. We are pleased to invite you to meet with us at CPHI Milan 2026, one of the most important events on the global pharmaceutical calendar. We look forward to connecting in person, sharing insights, and exploring new opportunities to collaborate.
Show Details
Event | CPHI Milan 2026 (World Pharma Europe) |
Dates | October 6–8, 2026 |
Venue | Fiera Milano, Italy |
Our Booth | 4K41 |
About Suzhou Tianji Biopharma
A core pharmaceutical arm of Suzhou Tianma Pharma Group, Suzhou Tianji has specialized in peptide therapeutics for more than 26 years, with a diversified pipeline across gastroenterology, women's health, infectious disease, pain management, oncology, and diabetes.
Our portfolio features high-value peptide assets, including:
· Tirzepatide, Semaglutide, and other GLP-1 receptor agonists
· Linaclotide — an oral cyclic peptide
· Peptide-Drug Conjugates (PDCs)
Our new state-of-the-art manufacturing campus in Changshu, Jiangsu, is now fully operational, with commercial-scale API and automated formulation lines. We provide integrated CRO, CMO, and CDMO services to partners worldwide, spanning the entire peptide value chain from early development through commercial supply.
We'd love to meet you in Milan.
Please visit us at Booth 4K41 to explore opportunities to work together.
To schedule a meeting, please reach out to us in advance.
See you in Milan!
Suzhou Tianji Biopharma Co., Ltd.
E-mail：peptide@tianmapharma.com